Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 11:50 am Sale | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | BIOTECHNOLOGY VALUE FUND L P | 6,260,311 10.5% | -1,171,251 (-15.76%) | View |
| 2023-02-01 4:55 pm Sale | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 2,663,000 4.5% | -12,000 (-0.45%) | View |
| 2023-01-26 10:27 am Sale | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | Swedbank Robur Fonder AB | 0 0% | -2,638,107 (Position Closed) | View |
| 2022-03-02 4:07 pm Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | Linc AB | 5,486,108 10.5% | 5,486,108 (New Position) | View |
| 2022-02-14 4:06 pm Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 2,675,000 5.1% | 2,675,000 (New Position) | View |
| 2022-02-14 08:53 am Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | Swedbank Robur Fonder AB | 2,638,107 5.04% | 2,638,107 (New Position) | View |
| 2020-11-12 5:11 pm Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | BIOTECHNOLOGY VALUE FUND L P | 7,431,562 14.9% | 2,650,000 (+55.42%) | View |
| 2020-06-08 10:27 am Purchase | 13G | CALLIDITAS THERAPEUTICS AB SPO CALT | BIOTECHNOLOGY VALUE FUND L P | 4,781,562 9.7% | 4,781,562 (New Position) | View |